Dr. Oxnard on the Role of Osimertinib in the TATTON Trial for Lung Cancer

Geoffrey R. Oxnard, MD
Published: Wednesday, Nov 01, 2017



Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.

The TATTON trial investigated osimertinib plus different combination therapies of durvalumab (Imfinzi), selumetinib, and savolitinib, states Oxnard.

Osimertinib with durvalumab was shown to be toxic, while osimertinib with selumetinib was found to be tolerable. Osimertinib and savolitinib is the combination that is moving forward to phase II development, explains Oxnard.
 


Geoffrey R. Oxnard, MD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the role of osimertinib (Tagrisso) in the TATTON trial for patients with lung cancer.

The TATTON trial investigated osimertinib plus different combination therapies of durvalumab (Imfinzi), selumetinib, and savolitinib, states Oxnard.

Osimertinib with durvalumab was shown to be toxic, while osimertinib with selumetinib was found to be tolerable. Osimertinib and savolitinib is the combination that is moving forward to phase II development, explains Oxnard.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x